A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: A single institution experience

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 2, 2009, Pages 117-123

  Curzio, Karen M ^a,b   Cheng Lai, A ^a   Kheyfets, V ^a   Sinnet, M ^a   Billett, H H ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b GRADY MEMORIAL HOSPITAL   (United States)

Author keywords

Direct thrombin inhibitors; Heparin induced thrombocytopenia

Indexed keywords

ARGATROBAN; HEPARIN; LEPIRUDIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOSIS;

AGED; ANTICOAGULANTS; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 67849097112     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0275-1     Document Type: Article

References (24)

1. Warkentin TE, Greinacher A, Koster A, Lincoff M (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:340-380S. doi: 10.1378/chest.08-0677
2. Chong BH (2003) Heparin-induced thrombocytopenia. J Thromb Haemost 1:1471-1478. doi: 10.1046/j.1538-7836.2003.00270.x
3. Warkentin TE (2003) Heparin-induced thrombocytopenia: Pathogenesis and management. Br J Haematol 121:535-555. doi: 10.1046/ j.1365-2141.2003.04334.x
4. Ahmed I, Majeed A, Poell R (2007) Heparin-induced thrombocytopenia-diagnosis and management update. Postgrad Med J 83:575-582. doi: 10.1136/pgmj.2007.059188
5. Efird LE, Kockler DR (2006) Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 40:1383-1387. doi: 10.1345/aph.1G738
6. Papadopoulos S, Flynn JD, Lewis DA (2007) Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy 27:921-926. doi: 10.1592/phco.27.6.921
7. Prechel M, Walenga JM (2008) The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: An update. Semin Thromb Hemost 34:86-96. doi: 10.1055/s-2008-1066027
8. Lewis BE, Wallis DE, Berkowitz SD et al (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838-1843
9. Clayton SB, Ascell JR, Crumble et al (2004) Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg 78:2167-2169. doi: 10.1016/S0003-4975(03)01471-1
10. Finks SW (2006) Bivalirudin use in carotid endarterectomy in a patient with heparin-induced thrombocytopenia. Ann Pharmacother 40:340-343. doi: 10.1345/aph.1G307
11. Greinacher A, Volpel H, Janssens U, HIT Investigators Group et al (1999) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 99:73-80
12. Lo GK, Sigouin CS, Warkentin TE (2007) What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82:1037-1043. doi: 10.1002/ajh.21032
13. Warkentin TE, Levine MN, Hirsh J et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 335:1330-1335. doi: 10.1056/ NEJM199505183322003
14. Warkentin TE (2004) An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 30:273-283. doi: 10.1055/s-2004-831039
15. Warkentin TE, Kelton JG (1996) A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502-507. doi: 10.1016/ S0002-9343(96)00258-6
16. Wallis DE, Workman DL, Lewis BE et al (1999) Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106:629-635. doi: 10.1016/S0002-9343(99)00124-2
17. Warkentin TE (2003) Management of heparin-induced thrombocytopenia: A critical comparison of lepirudin and argatroban. Thromb Res 110:73-82. doi: 10.1016/S0049-3848(03)00336-0
18. Greinacher A, Eichler P, Lubenow N et al (2000) Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT rage. Blood 96:846-851
19. Greinacher A, Lubenow N, Eichler P (2003) Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108:2062-2065. doi: 10.1161/ 01.CIR.0000096056.37269.14
20. Oliviera GB, Crespo EM, Becker RC et al (2008) Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 168:94-102. doi: 10.1001/ archinternmed.2007.65
21. Altuntas F, Matevosyan K, Burner J et al (2008) Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia. Eur J Haematol 80:429-435. doi: 10.1111/ j.1600-0609.2008.01035.x
22. Zwicker JI, Uhl L, Huang W et al (2004) Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2:2133-2137. doi: 10.1111/ j.1538-7836.2004.01039.x
23. Greinacher A, Juhl D, Strobel U et al (2007) Heparin-induced thrombocytopenia: A prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5:1666-1673. doi: 10.1111/j.1538-7836.2007.02617.x
24. Srinivasan AF, Rice L, Bartholomew JR et al (2004) Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 164:66-70. doi: 10.1001/ archinte.164.1.66